A new treatment for patients with primary advanced or recurrent womb cancer has been advised for use by the Scottish Medicines Consortium within NHS Scotland. This development means that patients in Scotland will get access to a treatment that may help them live longer lives.
The Scottish Medicines Consortium (SMC) has recommended patients with primary advanced or recurrent womb cancer receive pembrolizumab with chemotherapy as a combined first-line treatment.
Dr Eleanor Jones, Chair of Trustees at Peaches Womb Cancer Trust, said:
“This decision is very welcome news for patients living in Scotland. We hope that this is just the first step towards wider availability of more effective first-line treatment options for everyone affected by womb cancer.”
“This additional treatment for primary advanced and recurrent mismatch repair proficient and deficient endometrial cancer will provide much needed options for patients currently facing the reality of limited cancer treatments. Access to this innovative first-line treatment fills a significant unmet need.”
“Peaches Womb Cancer Trust has welcomed the opportunity to contribute to appraisals of pembrolizumab in both Scotland and England. We could not have done so without the contributions of Peaches Patient Voices, a group of people affected by womb cancer whose powerful testimonies and experiences informed our submissions.”
The decision made by SMC applies to those living in Scotland. A decision regarding approval for use in England is expected in due course.
